Application and product of nucleic acid aptamer and its modified warm-start reverse transcriptase
By developing nucleic acid aptamers and warm-start reverse transcriptase that specifically bind reverse transcriptase, the problem of primer dimer generation during low temperature storage is solved, the efficiency and stability of the PCR system is achieved, and the reaction is improved sensitivity and specificity.
Patent Information
- Application Number
- CN202411299563.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-18
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-09-18
Smart Images

Figure CN118813628B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of molecular diagnosis, and in particular relates to an application and product of a nucleic acid aptamer and a temperature-start reverse transcriptase modified therewith. Background Art
[0002] In the field of molecular diagnosis, the main method for nucleic acid amplification is still PCR technology. In the PCR process, there are two main methods for identifying nucleic acid amplification signals. One is to use fluorescent probes (such as TaqMan probes) that specifically bind to the target nucleic acid sequence and release fluorescent signals during the dissociation process to indicate the nucleic acid amplification results. The other is to use fluorescent dyes (such as SYBR) that non-specifically bind to double-stranded amplification products to release fluorescent signals. The former is more suitable for nucleic acid detection of specific diseases.
[0003] In nucleic acid detection, for DNA samples, in order to improve the specificity and sensitivity of the system, people generally choose to block the polymerase activity of Taq DNA polymerase, that is, hot start (Taq DNA polymerase does not show polymerase activity before thermal activation), so that it does not work before thermal activation and does not produce non-specific amplification such as primer dimers. When amplifying RNA samples, there is an additional step of reverse transcription, and RNA amplification also requires an additional reverse transcriptase. However, since the heat resistance of reverse transcriptase is not as high as that of Taq DNA polymerase, the same activity blocking method cannot be used. In this way, when the reagent is stored at low temperature, the primers in the system will slowly undergo non-specific amplification under the action of reverse transcriptase, that is, primer dimers. Primer dimers will also undergo PCR amplification, and their presence will consume the raw materials in the PCR system. Therefore, when the original concentration of the target nucleic acid is low, the competition of primer dimers will make the amplification result poor, which is manifested in poor amplification curve morphology and low fluorescence increment. This will greatly reduce the sensitivity and specificity of the PCR amplification system.
[0004] In commercial PCR amplification products, most manufacturers will choose to add Taq enzyme antibodies to block the activity of Taq enzyme at low temperatures, thereby preventing Taq enzyme from stimulating primer dimerization at low temperatures. During the denaturation stage of PCR amplification, Taq enzyme antibodies will be inactivated and lose the function of blocking Taq enzyme activity, which is called hot start of Taq enzyme in the field. However, since the working environment temperature of reverse transcriptase is not high (about 50°C), reverse transcriptase antibodies cannot be inactivated at this temperature. This also leads to the fact that there are few commercial raw materials on the market that can block reverse transcriptase activity at low temperatures, and reverse transcriptase hot start has become a technical problem. Summary of the invention
[0005] In order to solve the above problems, the present invention provides an application and product of a nucleic acid aptamer and a modified warm-start reverse transcriptase thereof. The present invention provides a nucleic acid aptamer that specifically binds to a reverse transcriptase, having any one or more nucleotide sequences as shown in SEQ ID NO.38-45, with a short production cycle and mature technology, suitable for large-scale commercial production. After the nucleic acid aptamer binds to the reverse transcriptase, the low-temperature activity of the reverse transcriptase is blocked, so that the 37°C exo-activity blocking rate is more than 98%, and the starting temperature reaches more than 37°C. By inhibiting the generation of secondary structures during low-temperature storage, the reaction solution can obtain reverse transcription products stably and efficiently for a long time, solving the problem of storage stability of the full premix. The prepared kit has good specificity, strong affinity, high sensitivity, fast reaction speed, low economic cost, good result repeatability, and accurate, objective and reliable data.
[0006] the term:
[0007] The "PHO" mentioned in the present invention stands for: phosphorylation modification.
[0008] The "ddc" described in the present invention represents: dideoxy modification.
[0009] The "Warm-Start M-MLV Reverse Transcriptase (III)" described in the present invention is a genetically engineered reverse transcriptase modified with an aptamer specially developed by the same family. It can achieve no reverse transcription activity below 37°C, and can completely release reverse transcription activity at 55°C without affecting cDNA synthesis and subsequent qPCR. It solves the problem that RT enzyme is prone to produce primer dimers during the preparation of RT-qPCR reaction at room temperature, provides higher system specificity, and maintains the original reverse transcriptase characteristics. Oligo dT, random primers or specific primers can be selected as reverse transcription primers as needed, and the obtained cDNA can be used for subsequent PCR, qPCR detection, cDNA library construction, etc. It provides strong support for the development of one-tube fully premixed RT-qPCR Mix. Unit definition: One unit of Warm-Start M-MLV ReverseTranscriptase (III) is the amount of enzyme required to catalyze the binding of 1 nmol dNTP to bacteriophage MS2 to form MS2 RNA / DNA complex within 10 minutes at 37°C.
[0010] To achieve the above purpose, the technical solution adopted by the present invention is as follows:
[0011] In a first aspect, the present invention provides a nucleic acid aptamer that specifically binds to reverse transcriptase, wherein the nucleic acid aptamer has any one or more nucleotide sequences as shown in SEQ ID NOs. 38-45.
[0012] Specifically, the nucleic acid aptamer has a nucleotide sequence as shown in SEQ ID NO.38, SEQ ID NO.39, SEQ ID NO.40, SEQ ID NO.41, SEQ ID NO.42, SEQ ID NO.43, SEQ ID NO.44 and / or SEQ ID NO.45.
[0013] More specifically, the nucleic acid aptamer has a nucleotide sequence as shown in SEQ ID NO.40 and / or SEQ ID NO.43.
[0014] Preferably, the nucleic acid aptamer has a nucleotide sequence as shown in SEQ ID NO.40.
[0015] Specifically, the 3' terminal base on the nucleotide sequence of the nucleic acid aptamer is phosphorylated, oxygen-methylated, methylated, amino-ated, dideoxy-ated or thiol-ated.
[0016] Specifically, the reverse transcriptase has an amino acid sequence as shown in SEQ ID NO.59.
[0017] Preferably, the method for preparing the reverse transcriptase comprises:
[0018] S1. Using homologous recombination, the DNA fragment containing the reverse transcriptase mutant gene sequence (SEQ ID NO.60) and the linearized pET28a vector were chemically transformed to obtain a recombinant plasmid. The recombinant plasmid was transferred into E. coli BL21 competent cells for culture, and then a single colony was selected for colony PCR screening of positive transformants. The bacteria were maintained, that is, the recombinant strain containing the reverse transcriptase mutant was prepared.
[0019] S2. The reverse transcriptase mutant is extracted and protein purified by crude enzyme to prepare reverse transcriptase.
[0020] In a second aspect, the present invention provides a use of the above-mentioned nucleic acid aptamer in modifying reverse transcriptase.
[0021] Specifically, the application includes: mixing the nucleic acid aptamer with the reverse transcriptase, and obtaining the warm-start reverse transcriptase after incubation.
[0022] More specifically, the mixing ratio of the reverse transcriptase and the nucleic acid aptamer is 10U:5-20μM.
[0023] Preferably, the mixing ratio of the reverse transcriptase and the nucleic acid aptamer is 10U: 5-10μM, 10U: 10-15μM or 10U: 15-20μM.
[0024] Further preferably, the mixing ratio of the reverse transcriptase and the nucleic acid aptamer is 10U:15-20μM.
[0025] Still more preferably, the mixing ratio of the reverse transcriptase and the nucleic acid aptamer is 10U:20μM.
[0026] Specifically, the incubation conditions are: incubation at 20-30°C for 1-3h.
[0027] Preferably, the incubation conditions are: incubation at 25°C for 2 hours.
[0028] In a third aspect, the present invention provides a warm-start reverse transcriptase, wherein the warm-start reverse transcriptase comprises: mixing the reverse transcriptase with the above-mentioned nucleic acid aptamer, and incubating to obtain the warm-start reverse transcriptase.
[0029] Specifically, the mixing ratio of the reverse transcriptase and the nucleic acid aptamer is 10U:5-20μM.
[0030] Preferably, the mixing ratio of the reverse transcriptase and the nucleic acid aptamer is 10U: 5-10μM, 10U: 10-15μM or 10U: 15-20μM.
[0031] Further preferably, the mixing ratio of the reverse transcriptase and the nucleic acid aptamer is 10U:15-20μM.
[0032] Still more preferably, the mixing ratio of the reverse transcriptase and the nucleic acid aptamer is 10U:20μM.
[0033] Specifically, the incubation conditions are: incubation at 20-30°C for 1-3h.
[0034] Preferably, the incubation conditions are: incubation at 25°C for 2 hours.
[0035] In a fourth aspect, the present invention provides a kit, comprising the above-mentioned nucleic acid aptamer or the above-mentioned warm-start reverse transcriptase.
[0036] Specifically, the kit is used for: pathogen detection, clinical disease diagnosis, tumor gene detection, in situ amplification, animal embryo identification, genetically modified food detection or environmental monitoring.
[0037] Specifically, the kit further comprises: one or more of PCR water, reverse transcription reaction buffer, dNTP, and reverse transcription reaction primer.
[0038] In a fifth aspect, the present invention provides the use of the above-mentioned nucleic acid aptamer, warm-start reverse transcriptase or kit in detecting nucleic acid, wherein the use is for non-disease diagnosis and treatment purposes.
[0039] Preferably, the nucleic acid comprises DNA and / or RNA.
[0040] Preferably, the nucleic acid aptamer, warm-start reverse transcriptase or kit is used for detecting nucleic acids of animals, plants and / or microorganisms.
[0041] The present invention has the following beneficial effects:
[0042] (1) The low-temperature activity of the reverse transcriptase modified with the nucleic acid aptamer provided by the present invention is blocked, and the starting temperature can reach above 37°C, which solves the problem of storage stability of the full premix solution of the kit such as RT-PCR, RT-qPCR, and cDNA synthesis. By inhibiting the generation of secondary structure during low-temperature storage, the reaction solution can obtain reverse transcription products stably and efficiently for a long time.
[0043] (2) The warm-start reverse transcriptase and kit prepared by the nucleic acid aptamer provided by the present invention have good specificity, strong affinity, high sensitivity, fast reaction speed, low economic cost, good result reproducibility, and accurate, objective and reliable data. BRIEF DESCRIPTION OF THE DRAWINGS
[0044] Figure 1 For the FAM channel (validation of warm-start reverse transcriptase performance).
[0045] Figure 2 For the VIC channel (Performance Verification of Warm-Start Reverse Transcriptase).
[0046] Figure 3 For the ROX channel (validation of warm-start reverse transcriptase performance).
[0047] Figure 4 For the Cy5 channel (Performance verification of warm-start reverse transcriptase).
[0048] Figure 5 For the FAM channel (37°C storage stability test).
[0049] Figure 6 It is the VIC channel (37°C storage stability test).
[0050] Figure 7 This is the ROX channel (37°C storage stability test).
[0051] Figure 8 For the CY5 channel (37°C storage stability test).
[0052] Fig. 9 The control enzyme NEB-M0380S-WarmStart® RTx Reverse Transcriptase was tested for activity blocking at 37°C and activity release at 50°C. The top 4 bars are tested at 37°C, and the bottom 4 bars are tested at 50°C.
[0053] Fig.10 The enzyme to be tested is Warm-Start M-MLV Reverse Transcriptase (Ⅲ), 100U / μL, activity blocking at 37℃ and activity release at 50℃; the top 4 strips are tested at 37℃, and the bottom 4 strips are tested at 50℃.
[0054] Fig.11 It is the FAM channel (the application of common reverse transcriptase in RT-qPCR reaction system).
[0055] Fig.12 It is the VIC channel (application of common reverse transcriptase in RT-qPCR reaction system).
[0056] Fig.13 It is the ROX channel (application of common reverse transcriptase in RT-qPCR reaction system).
[0057] Fig.14 This is the CY5 channel (application of common reverse transcriptase in RT-qPCR reaction system).
[0058] Fig.15 It is the FAM channel (application of warm-start reverse transcriptase in RT-qPCR reaction system).
[0059] Fig.16 VIC channel (application of warm-start reverse transcriptase in RT-qPCR reaction system).
[0060] Fig.17 ROX temperature control (application of warm start reverse transcriptase in RT-qPCR reaction system).
[0061] Fig.18 CY5 channel (application of warm-start reverse transcriptase in RT-qPCR reaction system). DETAILED DESCRIPTION
[0062] The specific embodiments of the present invention will be described in detail below. In order to avoid too much unnecessary details, the well-known structures or functions will not be described in detail in the following examples. Unless otherwise defined, the technical and scientific terms used in the following examples have the same meanings as those generally understood by those skilled in the art to which the present invention belongs.
[0063] Example 1 Sealing rate detection at different temperatures
[0064] The experimental system for the detection of blocking rate / release rate at 30°C, 32°C, 35°C, 37°C, and 50°C is shown in Table 1; the reaction procedure is shown in Table 2, using the Thermo Fisher Scientific real-time fluorescence quantitative PCR instrument QuantStudio™ 5 to select the SYBR fluorescence signal, and set the sample volume to 25 µL;
[0065] Calculation method of enzyme activity blocking rate / release rate: ΔRn=Rn signal value at 60 cycles-Rn signal value at 20 cycles, enzyme activity blocking rate / release rate=test group ΔRn÷control group ΔRn. At 37°C, the larger the ΔRn value, the lower the enzyme activity blocking rate under this temperature condition. At 50°C, the larger the ΔRn value, the higher the enzyme activity release rate under this temperature condition.
[0066] Table 1 Experimental system for detecting active sealing rate at different temperatures
[0067]
[0068] Table 2 Experimental system for detecting active sealing rate at different temperatures
[0069]
[0070] The nucleotide sequence of the MS2 RNA is shown in SEQ ID NO.58.
[0071] SEQ ID NO.58:
[0072]
[0073] Example 2 Preparation of reverse transcriptase
[0074] The thermostable M-MLV reverse transcriptase mutant (hereinafter referred to as reverse transcriptase) is obtained by subjecting the wild-type M-MLV reverse transcriptase to a series of site-directed mutagenesis, wherein the mutations include mutating the histidine at position 8 to tyrosine (H8Y), mutating the histidine at position 204 to arginine (H204R), mutating the asparagine at position 249 to aspartic acid (N249D), mutating the methionine at position 289 to leucine (M289L), and mutating the threonine at position 306 to The amino acid sequence of the reverse transcriptase is shown in SEQ ID NO. 59.
[0075] SEQ ID NO.59:
[0076] .
[0077] The preparation method of the reverse transcriptase comprises the following steps:
[0078] 1. Using the homologous recombination method, the DNA fragment containing the reverse transcriptase mutant gene sequence (SEQ ID NO.60) and the linearized pET28a vector are chemically transformed to obtain a recombinant plasmid. The recombinant plasmid is transferred into E. coli BL21 competent cells for culture, and then a single colony is selected for colony PCR screening of positive transformants, and the bacteria are maintained, that is, the recombinant strain containing the reverse transcriptase mutant is prepared. For the specific preparation method, please refer to paragraph [0102-0134] of patent CN116286721A.
[0079] 2. The reverse transcriptase mutant is purified by crude enzyme extraction to prepare the reverse transcriptase. The specific process is described in paragraph [0148-0175] of patent CN116286721A.
[0080] SEQ ID NO.60:
[0081]
[0082] Example 3 Screening of nucleic acid aptamers that specifically bind to reverse transcriptase
[0083] The nucleic acid aptamer used is artificially synthesized in vitro and synthesized by Pronopuhe Biotechnology Co., Ltd.; the nucleic acid aptamer sequence has more than 60% homology with the reverse transcriptase and can specifically bind to the DNA sequence of the reverse transcriptase; the nucleic acid aptamer can achieve warm start of the reverse transcriptase in the RT-PCR reaction system.
[0084] 1. First round of screening:
[0085] Reverse transcriptase and 25 aptamers were prepared in different ratios of 10U:2μM, 10U:5μM, 10U:10μM, and 10U:20μM, and then incubated at 25°C for about 2 hours for warm start, and then the blocking rate was tested at 37°C. The information of nucleic acid aptamers is shown in Table 3.
[0086] Table 3 Sequences and concentrations of first-round aptamers
[0087]
[0088]
[0089]
[0090] The experimental data of the above 25 aptamers are shown in Tables 4 and 5. Five aptamers with relatively high blocking rates were screened out, namely AP-RT-5, AP-RT-8, AP-RT-9, AP-RT-21 and AP-RT-22, and the ratio of thermostable M-MLV reverse transcriptase to aptamer was 10U:20μM.
[0091] Table 4 ΔRn under different proportions of aptamers
[0092]
[0093] Table 5 Blocking rate of residual enzyme activity at 37℃ with different proportions of aptamers
[0094]
[0095] 2. Second round of screening:
[0096] 2.1 Investigation of different proportions
[0097] For AP-RT-5, AP-RT-8, AP-RT-9, AP-RT-21 and AP-RT-22 in the first round of screening, reverse transcriptase and aptamer were prepared in different ratios (10U: 5μM, 10U: 10μM, 10U: 20μM), incubated at 25℃ for about 2 hours for warm start, and then tested for blocking rate at 30℃ and 37℃. The information of nucleic acid aptamers is shown in Table 6, and the screening results are shown in Tables 7-8.
[0098] Table 6 Second round of aptamer screening
[0099]
[0100] Table 7 ΔRn under different proportions of aptamers
[0101]
[0102] Table 8 Blocking rate of residual enzyme activity at 30℃ / 37℃ with different proportions of aptamers
[0103]
[0104] The above results show that the enzyme activity of AP-RT-9 was not blocked at 30°C; the enzyme activity of AP-RT-5, AP-RT-8, AP-RT-21, and AP-RT-22 was completely blocked at 30°C when the enzyme to aptamer ratio was 10U:20μM, but the enzyme activity was partially blocked at 37°C.
[0105] 2.2 Determination of sealing rate at different temperatures
[0106] Reverse transcriptase and aptamer AP-RT-5 / AP-RT-8 / AP-RT-21 / AP-RT-22 were prepared at a ratio of 10U:20μM and incubated at 25°C for about 2 hours for warm start. The enzyme activity blocking rate was detected at different temperatures of 30°C, 32°C, 35°C, and 37°C. The experimental results are shown in Table 9.
[0107] Table 9 Enzyme activity blocking rate of aptamers at 10U:20μM input
[0108]
[0109] The test results show:
[0110] At 30°C: the activities of AP-RT-5, AP-RT-8, AP-RT-21, and AP-RT-22 were all blocked;
[0111] At 32°C: AP-RT-21 activity was blocked; AP-RT-5, AP-RT-8, and AP-RT-22 showed partial activity;
[0112] At 35℃ / 37℃: AP-RT-5, AP-RT-8, AP-RT-21, and AP-RT-22 all showed partial activity.
[0113] 3. The third round of screening:
[0114] Combining the above two rounds of screening experience, 20 aptamers as shown in Table 10 were synthesized, and reverse transcriptase and aptamer were prepared in the ratio of 10U:20μM, 10U:40μM, 10U:60μM, and 10U:80μM, and then incubated at 25°C for about 2 hours for warm start, and then the blocking rate was detected at 37°C.
[0115] Table 10 Sequences and concentrations of nucleic acid aptamers in the third round
[0116]
[0117]
[0118] Two aptamers, AP-RT-32 and AP-RT-38, were screened out and could completely block the enzyme activity at 37°C at a ratio of 10U:20μM (reverse transcriptase:aptamer) (Table 11). Among them, AP-RT-32 was superior to AP-RT-38.
[0119] Table 11 Blocking rate of residual enzyme activity at 37℃ with different proportions of aptamers
[0120]
[0121] In the above experimental results, when the ratio of enzyme to aptamer was 10U:20μM, the aptamer with a 37°C blocking rate of 100% was tested again for 37°C enzyme activity blocking rate and 50°C enzyme activity release rate. The test results are shown in Tables 12 and 13 below:
[0122] Table 12 Enzyme activity blocking rate at 37℃
[0123]
[0124] Table 13 Enzyme activity blocking rate at 50℃
[0125]
[0126] At a ratio of reverse transcriptase:aptamer = 10U:20μM:
[0127] There are two completely blocked aptamers, AP-RT-32 and AP-RT-38; the next best blocked aptamer is AP-RT-31, with a residual blocking rate of 2.02% at 37°C; the other three with a residual blocking rate of less than 5% at 37°C are AP-RT-21-C, AP-RT-33, and AP-RT-35. In this experiment, the enzyme activity release rates of the eight aptamers at 50°C were all greater than 99%.
[0128] 4. The fourth round of screening: Two completely closed aptamers, AP-RT-32 and AP-RT-38, were selected for different batches to verify the stability of the trial production process.
[0129] Reverse transcriptase and aptamers AP-RT-32 and AP-RT-38 were prepared at a ratio of 10U:20μM, respectively, and incubated at 25°C for about 2 hours for warm start modification, and then the blocking rate was detected at 37°C.
[0130] Specifically, prepare a single reaction according to Table 14 below, and prepare according to the required number of reactions. After the preparation is completed, divide it into 25 μL per reaction and react on the machine. The test conditions are 37°C 30 seconds / cycle, 60 cycles; 50°C 30 seconds / cycle, 60 cycles.
[0131] Table 14 Single reaction preparation
[0132]
[0133] The experiment tested three batches of unmodified original enzyme, AP-RT-32 modified warm start reverse transcriptase, and AP-RT-38 modified warm start reverse transcriptase. Two aptamer modified mutant reverse transcriptases were tested, and the test results are shown in Table 15 below.
[0134] Table 15 Reverse transcription activity detection of AP-RT-32 / AP-RT-38 modified reverse transcriptase at different temperatures
[0135]
[0136] The experimental results show that aptamers AP-RT-32 and AP-RT-38 can completely block the reverse transcriptase activity of the mutant reverse transcriptase at 37°C. At the same time, the activity can be basically completely released at 50°C. Specifically, the overall performance of aptamer AP-RT-32 is slightly better than that of aptamer AP-RT-38, but both can meet the product development concept, that is, to achieve the reverse transcriptase warm start effect (the reverse transcriptase activity at 37°C and below is blocked as much as possible, and the reverse transcriptase activity at 50°C and above is released as much as possible).
[0137] Example 4 Reverse transcriptase activity detection method
[0138] AP-RT-32 is the aptamer of the best reverse transcriptase. After the reverse transcriptase and AP-RT-32 are mixed at a ratio of 10U:20μM, they are incubated at 25°C for 2 hours for warm start, which is the warm-start reverse transcriptase Warm-Start M-MLV ReverseTranscriptase (Ⅲ).
[0139] The reverse transcriptase without warm start (no aptamer and no incubation) and the warm start reverse transcriptase were tested respectively, and the enzyme activity blocking test was performed at 37°C, and the residual blocking rate of the warm start reverse transcriptase activity was calculated to be 0; the enzyme activity release rate was tested at 50°C, and the activity release rate of the warm start reverse transcriptase was calculated to be 100%. The test results are shown in Table 16. It shows that the activity of the warm start reverse transcriptase is completely blocked at 37°C, and the activity is released at 50°C.
[0140] Calculation method of enzyme activity blocking rate / release rate: ΔRn=Rn signal value at 60 cycles-Rn signal value at 20 cycles, enzyme activity blocking rate / release rate=test group ΔRn÷control group ΔRn. At 37°C, the larger the ΔRn value, the lower the enzyme activity blocking rate under this temperature condition. At 50°C, the larger the ΔRn value, the higher the enzyme activity release rate under this temperature condition.
[0141] Table 16 Enzyme activity blocking test results
[0142]
[0143] Example 5 Performance verification of warm-start reverse transcriptase
[0144] 1. Template preparation
[0145] Human Hela cell total RNA (Human Hela Cell Total RNA, purchased from TaKaRa, catalog number PK0495) was diluted with water in a gradient manner. The dilution gradient and concentration are shown in Table 17.
[0146] Table 17 Hlea RNA dilution gradient and concentration
[0147]
[0148] 2. Experimental system and reaction procedure
[0149] The performance verification experimental system is shown in Table 18, the Hela RNA primer probe quadruple mix sequence in Table 18 is shown in Table 19, and the reaction procedure is shown in Table 20.
[0150] Table 18 Performance verification test system
[0151]
[0152] Table 19 Hela RNA primer probe quadruple mix sequence
[0153]
[0154]
[0155] Table 20 Performance Verification Reaction Procedure
[0156]
[0157] 3. Performance Verification
[0158] The experiment was divided into a normal reverse transcriptase group and a warm-start reverse transcriptase group.
[0159] (1) Ordinary reverse transcriptase group: no adapter added and no incubation (no warm start treatment).
[0160] (2) Warm-Start M-MLV Reverse Transcriptase (Ⅲ): Mix the reverse transcriptase and aptamer AP-RT-32 at a ratio of 10 U: 20 μM, and incubate at 25°C for 2 hours for warm start, which is the warm-start reverse transcriptase.
[0161] The results of the test are shown in Figure 1-Figure 4 In the figure, the pink color represents the normal reverse transcriptase system, and the black color represents the warm-start reverse transcriptase system. Figure 1 This is a comparison chart of FAM channels. Figure 2 This is a comparison chart of VIC channels. Figure 3 This is a comparison chart of ROX channels. Figure 4 This is a comparison chart of the CY5 channel. The warm-start reverse transcriptase system showed better specificity in the ROX and CY5 channels: low copies maintained better peak shapes.
[0162] Example 6 Performance stability test of warm-start reverse transcriptase
[0163] The experiment was divided into a normal reverse transcriptase group and a warm-start reverse transcriptase group:
[0164] (1) Ordinary reverse transcriptase group: no adapter added and no incubation (no warm start treatment).
[0165] (2) Warm-Start M-MLV Reverse Transcriptase (Ⅲ).
[0166] After reverse transcriptase and AP-RT-32 were mixed at a ratio of 10U:20μM, they were incubated at 25°C for 2 hours for warm start, which is warm start reverse transcriptase.
[0167] The common reverse transcriptase or warm start reverse transcriptase was divided into 5 portions, 1 portion was stored at -20°C, and the other 4 portions were stored at 37°C for 1 / 3 / 5 / 7 days respectively. The functional stability comparison test was performed in the RT-qPCR system. The experimental system is shown in Table 18-Table 19, and the reaction procedure is shown in Table 20.
[0168] The results of the test are shown in Figure 5-Figure 8 The signal value of ordinary reverse transcriptase (DZ) without nucleic acid aptamers in the RT-qPCR system decreased gradually with the decrease of template copy number input, while the signal value and CT value of warm-start reverse transcriptase with nucleic acid aptamers did not change significantly when stored at 37℃ for 1 / 3 / 5 / 7 days.
[0169] Example 7 Comparison of performance of competing products
[0170] Control enzyme: NEB WarmStart® RTx Reverse Transcriptase, 15U / μL;
[0171] Enzyme to be tested: Warm-Start M-MLV Reverse Transcriptase (Ⅲ), 100 U / μL;
[0172] The control enzyme and the test enzyme were diluted to 1U / μL with 1× RT activity detection buffer and tested according to the detection system described in Table 21 and the experimental conditions described in Table 22. The test results are shown in Figure 9-10 And as shown in Table 23.
[0173] Table 21 Detection system
[0174]
[0175] Table 22 Experimental conditions
[0176]
[0177] Table 23 Measurement results
[0178]
[0179] The activities of the control enzyme and the test enzyme temperature-started reverse transcriptase were completely blocked at 37°C, but the enzyme activity release rate of the test enzyme was much higher than that of the control enzyme at 50°C.
[0180] Example 8 Application of reverse transcriptase nucleic acid aptamers in RT-qPCR reaction system
[0181] The experiment was divided into a common reverse transcriptase group and a warm-start reverse transcriptase group. The common reverse transcriptase or warm-start reverse transcriptase products were put into a tube of RT-qPCR premix solution and stored in a -20°C and 37°C incubator, respectively. The system performance stability was tested after 3 days.
[0182] (1) Common reverse transcriptase group
[0183] No warm start treatment was performed, i.e., the reverse transcriptase was not added with the adapter and was not incubated.
[0184] (2) Warm start reverse transcriptase group
[0185] Warm-Start M-MLV Reverse Transcriptase(Ⅲ): Mix reverse transcriptase and AP-RT-32 at a ratio of 10U:20μM and incubate at 25℃ for 2 hours for warm start, which is warm-start reverse transcriptase.
[0186] 1. Template preparation
[0187] Hlea RNA was diluted with water for serial dilutions. The dilution gradient and concentrations are shown in Table 24.
[0188] Table 24 Template dilution gradient
[0189]
[0190] 2. Experimental system
[0191] The experimental system is shown in Table 25.
[0192] Table 25 Experimental system
[0193]
[0194] 3. Reaction procedure
[0195] The reaction procedure is shown in Table 26.
[0196] Table 26 Reaction procedure
[0197]
[0198] The results of the test are as follows Figure 11-Figure 18 As shown, with -20℃ as the control, from the results of storage at 37℃ for 3 days, it can be seen that the signal value of the system with warm-start reverse transcriptase added to the system decreased less than that of the system with ordinary reverse transcriptase added; therefore, warm-start reverse transcriptase has the effect of enhancing the stability of the one-step RT-qPCR Mix (fully premixed) system.
[0199] The above detailed description is a specific description of one of the feasible embodiments of the present invention, and the embodiment is not intended to limit the scope of the present invention. It should be pointed out that any equivalent implementation or change that does not deviate from the present invention should be included in the scope of the technical solution of the present invention. Therefore, the protection scope of the patent of the present invention shall be based on the attached requirements.
Claims
1. A nucleic acid aptamer that specifically binds to reverse transcriptase, characterized in that: The nucleotide sequence of the nucleic acid aptamer is shown in SEQ ID NO.40 or SEQ ID NO.
43.
2. The nucleic acid aptamer according to claim 1, characterized in that The 3' terminal base on the nucleotide sequence of the nucleic acid aptamer is phosphorylated, oxygen-methylated, methylated, amino-ated, dideoxy-ated or thiol-ated.
3. The nucleic acid aptamer according to claim 2, characterized in that The amino acid sequence of the reverse transcriptase is shown in SEQ ID NO.
59.
4. Use of the nucleic acid aptamer according to any one of claims 1 to 3 in modifying reverse transcriptase.
5. A warm-start reverse transcriptase, characterized in that The warm-start reverse transcriptase comprises: mixing the reverse transcriptase with the nucleic acid aptamer according to any one of claims 1 to 3, and incubating to obtain the warm-start reverse transcriptase.
6. The warm-start reverse transcriptase according to claim 5, characterized in that The mixing ratio of the reverse transcriptase and the nucleic acid aptamer is 10U:5-20μM.
7. The warm-start reverse transcriptase according to claim 5, characterized in that The incubation conditions are: incubation at 20-30°C for 1-3h.
8. A kit, characterized in that: The kit comprises the nucleic acid aptamer according to any one of claims 1 to 3 or the warm-start reverse transcriptase according to any one of claims 5 to 7.
9. The kit according to claim 8, characterized in that The kit is used for pathogen detection, clinical disease diagnosis, tumor gene detection, in situ amplification, animal embryo identification, genetically modified food detection or environmental monitoring.
10. Use of the nucleic acid aptamer according to any one of claims 1 to 3, the warm-start reverse transcriptase according to any one of claims 5 to 7, or the kit according to claim 8 in detecting nucleic acids, wherein the use is for non-disease diagnosis and treatment purposes.
Citation Information
Patent Citations
Heat-resistant reverse transcriptase mutant as well as preparation method and application thereof
CN116286721A
Aptamer AS1411 subjected to chemical modification and application thereof
CN105296491A
Aptamer specifically binding to reverse transcriptase and application thereof
CN113355329A
Aptamer specifically combined with H-FABP and application thereof
CN117343933A
One-tube RT-qpcr fully premixed reaction reagent, use, and RT-qpcr method
WO2024045461A1
